The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion. Wide-moat GSK’s third-quarter earnings aligned with our ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

and robust product delivery practices, including building supply capacity. The drugmaker's chief executive, Emma Walmsley noted this is the eighth time that GSK had headed the list, and comes ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

While GSK insists it is still firmly focused on R&D, the company has latterly started to increase its portfolio of high-volume, lower-priced products, such as vaccines and consumer healthcare ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

The Nigerian economy has seen the closure of many companies, especially multinational firms, which threw many Nigerians into ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GlaxoSmithKline ( (GSK) ) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... and data readouts supporting future product momentum. So far this year ...

Shares of GSK fell over 3% following its third-quarter 2024 earnings, as investors reacted to underwhelming sales figures in ...